Abstract:Introduction The gold standard treatment of stage I non-small cell lung cancer (NSCLC) is surgical resection. For medically inoperable patients, stereotactic body radiation therapy (SBRT) can provide comparable local control (LC) and overall survival (OS). The objectives of this study are to determine the three-year LC and OS for SBRT compared to early-stage NSCLC patients treated with alternative radiation modalities at our institution. Materials and methods This retrospective study included a total of 139 consecutive patients who were diagnosed with stage I (T1-2 N0 M0) NSCLC and treated with radiation therapy at our institution between 2015 and 2020. Patient demographics and clinical data were obtained from chart reviews. Treatment subgroups were: SBRT (48Gy/4 or 60Gy/8), hypofractionation (60Gy/15), conventional fractionation (60Gy/30 or 50Gy/20), and palliative radiation (20Gy/5, 30Gy/10, or 40Gy/15). Kaplan-Meier curves were plotted for LC and OS. We also performed Cox's proportional hazard regression analysis. Results The median patient age was 74 (range 52-91). The numbers of patients in each treatment subgroup were: SBRT (44), hypofractionation (78), conventional fractionation (8), and palliative (9). Differences in age, gender, and histopathological cell type between subgroups were not statistically significant. Metastatic progression was the most common outcome amongst treatment failures, followed by local recurrence and regional spread. Median post-treatment follow-up in months for each subgroup was: SBRT (20.2), hypofractionated (20.7), conventional fractionation (13.9), and palliative (14.4). Post-treatment three-year LC was found to be significantly better with SBRT (94%) versus hypofractionation (71%), conventional fractionation (80%), and palliative (71%). OS at three years were SBRT (67%), hypofractionation (59%), conventional fractionation (66%), and palliative (44%). As a whole, 72% (100/139) of patients had biopsy-proven NSCLC. Analysis showed biopsy status had no statistical significance with regards to LC or OS. Every 20 years of age had a 3.2x risk of death (95% CI: 1.425-7.268). Concerning the treatment modalities, there were significant differences for the hazard of death compared to SBRT: hypofractionation had 2.58x increased risk while palliative had 5.83x increased risk. The proportion of patients who experienced post-treatment radiation pneumonitis or dermatitis were: SBRT (7%, 2%), hypofractionation (8%, 3%), conventional fractionation (13%, 25%), and palliative (0%, 0%), respectively. No patients who experienced grade III or higher toxicities were observed as defined by Common Terminology Criteria for Adverse Events (CTCAE). Conclusion Our experience confirms SBRT can provide durable three-year local control with a comparable rate of post-treatment complications versus other radiation modalities for early-stage NSCLC. SBRT appears to be non-inferior to hypofractionation with regards to three-year LC.

Outcomes of stereotactic body radiotherapy in patients with stage Ⅲ non-small cell lung cancer

Correction: Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study

Clinical Analysis of Stereotactic Body Radiation Therapy Using Extracranial Gamma Knife for Patients with Mainly Bulky Inoperable Early Stage Non-Small Cell Lung Carcinoma

P3.16-19 Clinical Outcomes of Stereotactic Body Radiation Therapy for T2N0M0 Non-Small Cell Lung Cancer

Clinical Outcomes of CyberKnife Stereotactic Body Radiotherapy for Peripheral Stage I Non-Small Cell Lung Cancer

Clinical Outcomes of Stereotactic Body Radiation Therapy for T2N0M0 Non-Small Cell Lung Cancer

Outcome Study of Cobalt Based Stereotactic Body Radiation Therapy for Patients with Inoperable Stage III Non-small Cell Lung Cancer

Early-Stage Non-Small Cell Lung Cancer Stereotactic Body Radiation Therapy Outcomes in a Single Institution

Three Dimensional-conformal Radiotherapy Combined Concurrent Chemotherapy with Vinorelbine and Cisplatin for Stage Ⅲ Non-small Cell Lung Cancer

Clinical Outcomes of Stereotactic Body Radiotherapy for De Novo Pulmonary Tumors in Patients with Completely Resected Early Stage Non-Small Cell Lung Cancer

Outcomes of Image-Guided Moderately Hypofractionated Radiotherapy for Stage III Non-Small-Cell Lung Cancer

Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study

A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy in inoperable stage I non-small cell lung cancer.

Therapeutic Evaluation of Postoperative Radiotherapy for Patients with Completely Resected Stage IIIa(N_2) Non-Small Cell Lung Cancer

Clinical analysis of stereotactic radiotherapy for primary non-small-cell lung cancer

Four-year follow-up outcomes after stereotactic body radiation therapy for central early-stage non-small cell lung cancer

Efficacy of stereotactic body radiotherapy in treatment of early-stage peripheral non-small cell lung cancer

Comparison of the Outcomes of Sublobar Resection and Stereotactic Body Radiotherapy for Stage T1-2N0M0 Non-Small Cell Lung Cancer with Tumor Size ≤ 5 Cm: a Propensity Score Matching Analysis.

Survival Outcome after Stereotactic Body Radiation Therapy and Surgery for Stage I Non-Small Cell Lung Cancer: a Meta-Analysis.

A Meta-Analysis Comparing Stereotactic Body Radiotherapy Vs Conventional Radiotherapy in Inoperable Stage I Non-Small Cell Lung Cancer

Clinical Observation of Stereotactic Body Radiation Therapy for Early Stage Non-small Cell Lung Cancer